Immunotherapy of a murine tumor with interleukin 2. Increased sensitivity after MHC class I gene transfection
- PMID: 3500265
- PMCID: PMC2188791
- DOI: 10.1084/jem.166.6.1716
Immunotherapy of a murine tumor with interleukin 2. Increased sensitivity after MHC class I gene transfection
Abstract
We have shown that two weakly immunogenic MCA sarcomas developed in our laboratory that are sensitive to high-dose IL-2 immunotherapy express class I MHC in vivo and in vitro. Two nonimmunogenic MCA sarcomas are relatively insensitive to IL-2 therapy and express minimal or no class I MHC molecules in vivo and in vitro. To study the role of MHC in the therapy of tumors with IL-2, a class I-deficient murine melanoma, B16BL6, was transfected with the Kb class I gene. Expression of class I MHC rendered B16BL6 advanced pulmonary macrometastases sensitive to IL-2 immunotherapy. 3-d micrometastases of CL8-2, a class I transfected clone of B16BL6, were significantly more sensitive to IL-2 therapy than a control nontransfected line. Expression of Iak, a class II MHC molecule, had no effect on IL-2 therapy of transfectant pulmonary micrometastases in F1 mice. By using lymphocyte subset depletion with mAbs directed against Lyt-2, therapy of class I transfectant macrometastases with high-dose IL-2 was shown to involve an Lyt-2 cell. In contrast, regression of micrometastases treated with low-dose IL-2 involved Lyt-2+ cells, but regression mediated by high doses of IL-2 did not. We hypothesize that both LAK and Lyt-2+ T cells effect IL-2-mediated elimination of micrometastases, but only Lyt-2+ T cells are involved in macrometastatic regression. Low doses of IL-2 stimulate Lyt-2+ cells to eliminate class I-expressing micrometastases, but high doses of IL-2 can recruit LAK cells to mediate regression of micrometastases independent of class I expression. Only high-dose IL-2, mediating its effect predominantly via Lyt-2+ cells, is capable of impacting on MHC class I-expressing macrometastases. Macrometastases devoid of class I MHC antigens appear to be resistant to IL-2 therapy.
Similar articles
-
Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2.J Immunol. 1987 Jul 1;139(1):285-94. J Immunol. 1987. PMID: 3108401
-
Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.J Immunol. 1988 Aug 1;141(3):1047-53. J Immunol. 1988. PMID: 3260908
-
Characterization of two distinct primary T cell populations that secrete interleukin 2 upon recognition of class I or class II major histocompatibility antigens.J Exp Med. 1986 Mar 1;163(3):603-19. doi: 10.1084/jem.163.3.603. J Exp Med. 1986. PMID: 2936862 Free PMC article.
-
Role of the major histocompatibility complex in resistance to viral leukemia; its effect on the preleukemic stage of leukemogenesis.Springer Semin Immunopathol. 1982;4(4):373-96. doi: 10.1007/BF02053740. Springer Semin Immunopathol. 1982. PMID: 6293111 Review. No abstract available.
-
Altered MHC class I antigens in tumors.Int J Clin Lab Res. 1997;27(2):95-102. doi: 10.1007/BF02912442. Int J Clin Lab Res. 1997. PMID: 9266279 Review.
Cited by
-
Defective presentation of endogenous antigens by a murine sarcoma. Implications for the failure of an anti-tumor immune response.J Immunol. 1991 Aug 15;147(4):1453-9. J Immunol. 1991. PMID: 1907999 Free PMC article.
-
Increased projection of MHC and tumor antigens in murine B16-BL6 melanoma induced by hydrostatic pressure and chemical crosslinking.Cancer Immunol Immunother. 1993 May;36(5):293-9. doi: 10.1007/BF01741167. Cancer Immunol Immunother. 1993. PMID: 8477415 Free PMC article.
-
Amplification of altered self-reactive cytolytic T lymphocyte responses by cloned, allospecific human Th cells.J Clin Invest. 1988 Nov;82(5):1722-30. doi: 10.1172/JCI113786. J Clin Invest. 1988. PMID: 3263397 Free PMC article.
-
Effect of allogeneic tumor cells, interleukin-2 and interleukin-6, on the growth of subcutaneous syngeneic tumors.Cancer Immunol Immunother. 1993 Sep;37(4):233-9. doi: 10.1007/BF01518516. Cancer Immunol Immunother. 1993. PMID: 8348562 Free PMC article.
-
Decrease in lymphokine-activated killer sensitivity of a human renal-cell carcinoma cell line after cytokine treatment.Cancer Immunol Immunother. 1994 Jul;39(1):22-6. doi: 10.1007/BF01517176. Cancer Immunol Immunother. 1994. PMID: 7913877 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials